Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 15 | 2025 | 498 | 4.190 |
Why?
|
| Cerebrovascular Circulation | 8 | 2025 | 225 | 3.080 |
Why?
|
| Vasodilation | 9 | 2025 | 115 | 2.910 |
Why?
|
| Fluconazole | 3 | 2025 | 12 | 2.770 |
Why?
|
| Hand Strength | 8 | 2026 | 39 | 2.020 |
Why?
|
| Cytochrome P-450 CYP2C9 Inhibitors | 2 | 2025 | 4 | 1.850 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2025 | 5 | 1.850 |
Why?
|
| Muscle, Skeletal | 10 | 2026 | 641 | 1.670 |
Why?
|
| Cognition | 6 | 2026 | 331 | 1.450 |
Why?
|
| Nitric Oxide Synthase | 4 | 2021 | 34 | 1.280 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2021 | 24 | 1.280 |
Why?
|
| Cerebral Arteries | 3 | 2019 | 33 | 1.200 |
Why?
|
| Forearm | 8 | 2026 | 40 | 1.200 |
Why?
|
| Young Adult | 16 | 2026 | 2842 | 1.080 |
Why?
|
| Rest | 2 | 2025 | 96 | 1.070 |
Why?
|
| Adult | 22 | 2026 | 8048 | 1.030 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2025 | 5 | 0.950 |
Why?
|
| Hypovolemia | 1 | 2025 | 5 | 0.950 |
Why?
|
| Exercise Test | 4 | 2020 | 249 | 0.930 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2025 | 35 | 0.930 |
Why?
|
| Vasoconstriction | 1 | 2025 | 45 | 0.890 |
Why?
|
| Sympathetic Nervous System | 1 | 2025 | 68 | 0.880 |
Why?
|
| Smartphone | 1 | 2025 | 80 | 0.880 |
Why?
|
| Cancer Survivors | 1 | 2025 | 72 | 0.860 |
Why?
|
| Regional Blood Flow | 8 | 2025 | 164 | 0.820 |
Why?
|
| Stress, Psychological | 1 | 2026 | 233 | 0.810 |
Why?
|
| Female | 23 | 2026 | 15690 | 0.800 |
Why?
|
| Male | 24 | 2026 | 13983 | 0.800 |
Why?
|
| Double-Blind Method | 4 | 2025 | 426 | 0.780 |
Why?
|
| Boxing | 1 | 2022 | 3 | 0.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 344 | 0.710 |
Why?
|
| Humans | 31 | 2026 | 28998 | 0.710 |
Why?
|
| Hot Temperature | 1 | 2022 | 87 | 0.710 |
Why?
|
| High-Intensity Interval Training | 1 | 2020 | 9 | 0.660 |
Why?
|
| Executive Function | 1 | 2020 | 27 | 0.650 |
Why?
|
| Blood Flow Velocity | 5 | 2025 | 66 | 0.640 |
Why?
|
| Endothelium, Vascular | 3 | 2025 | 334 | 0.620 |
Why?
|
| omega-N-Methylarginine | 5 | 2021 | 11 | 0.590 |
Why?
|
| Hypoxia | 1 | 2019 | 90 | 0.590 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2017 | 2 | 0.540 |
Why?
|
| Sildenafil Citrate | 1 | 2017 | 4 | 0.540 |
Why?
|
| Neoplasms | 1 | 2025 | 879 | 0.490 |
Why?
|
| Middle Cerebral Artery | 3 | 2025 | 54 | 0.470 |
Why?
|
| Lower Body Negative Pressure | 2 | 2025 | 5 | 0.470 |
Why?
|
| Neurovascular Coupling | 3 | 2022 | 154 | 0.450 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 41 | 0.450 |
Why?
|
| Cross-Over Studies | 2 | 2025 | 139 | 0.450 |
Why?
|
| Cyclooxygenase Inhibitors | 4 | 2021 | 25 | 0.430 |
Why?
|
| Oxygen Consumption | 4 | 2019 | 190 | 0.400 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2021 | 75 | 0.390 |
Why?
|
| Sex Factors | 3 | 2025 | 470 | 0.380 |
Why?
|
| Brachial Artery | 3 | 2025 | 37 | 0.380 |
Why?
|
| Blood Pressure | 3 | 2023 | 358 | 0.370 |
Why?
|
| Peripheral Arterial Disease | 2 | 2025 | 144 | 0.340 |
Why?
|
| Hemodynamics | 4 | 2021 | 221 | 0.340 |
Why?
|
| Adolescent | 5 | 2026 | 3223 | 0.330 |
Why?
|
| Ventilators, Mechanical | 1 | 2009 | 10 | 0.310 |
Why?
|
| Fires | 1 | 2009 | 12 | 0.310 |
Why?
|
| Caffeine | 1 | 2009 | 39 | 0.310 |
Why?
|
| Ketorolac | 3 | 2021 | 9 | 0.280 |
Why?
|
| Healthy Volunteers | 2 | 2025 | 50 | 0.260 |
Why?
|
| Resistance Training | 2 | 2022 | 212 | 0.260 |
Why?
|
| Pilot Projects | 2 | 2025 | 464 | 0.260 |
Why?
|
| Isometric Contraction | 1 | 2026 | 119 | 0.230 |
Why?
|
| Niacinamide | 1 | 2025 | 32 | 0.220 |
Why?
|
| Sleep Deprivation | 2 | 2021 | 28 | 0.220 |
Why?
|
| NAD | 1 | 2025 | 104 | 0.210 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 251 | 0.210 |
Why?
|
| Middle Aged | 6 | 2025 | 7428 | 0.210 |
Why?
|
| Prefrontal Cortex | 2 | 2021 | 80 | 0.200 |
Why?
|
| Aged | 5 | 2025 | 5608 | 0.200 |
Why?
|
| Circulating MicroRNA | 1 | 2022 | 10 | 0.190 |
Why?
|
| Obesity | 2 | 2021 | 702 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2025 | 273 | 0.190 |
Why?
|
| Acclimatization | 1 | 2022 | 31 | 0.180 |
Why?
|
| Athletes | 1 | 2022 | 70 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2021 | 55 | 0.180 |
Why?
|
| Quality of Life | 1 | 2025 | 523 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2021 | 48 | 0.170 |
Why?
|
| Citrulline | 1 | 2020 | 3 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2021 | 20 | 0.160 |
Why?
|
| Isoproterenol | 2 | 2021 | 23 | 0.160 |
Why?
|
| Menstrual Cycle | 1 | 2020 | 24 | 0.160 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 79 | 0.160 |
Why?
|
| Indomethacin | 1 | 2019 | 15 | 0.160 |
Why?
|
| Random Allocation | 1 | 2019 | 152 | 0.150 |
Why?
|
| Brain | 2 | 2021 | 770 | 0.150 |
Why?
|
| Heart Rate | 1 | 2020 | 382 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2022 | 303 | 0.140 |
Why?
|
| Biomarkers | 2 | 2019 | 782 | 0.140 |
Why?
|
| Oxygen | 1 | 2019 | 237 | 0.140 |
Why?
|
| Muscle Strength | 2 | 2021 | 230 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 271 | 0.140 |
Why?
|
| Cyclic GMP | 1 | 2017 | 29 | 0.130 |
Why?
|
| Aging | 2 | 2022 | 1019 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 22 | 0.120 |
Why?
|
| Vascular Resistance | 1 | 2015 | 50 | 0.110 |
Why?
|
| Muscle Contraction | 1 | 2015 | 171 | 0.110 |
Why?
|
| Ascorbic Acid | 1 | 2014 | 24 | 0.110 |
Why?
|
| Biochemical Phenomena | 1 | 2014 | 2 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2016 | 176 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2015 | 175 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2015 | 243 | 0.100 |
Why?
|
| Fatigue | 1 | 2014 | 66 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 80 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 301 | 0.100 |
Why?
|
| Exercise Tolerance | 1 | 2014 | 82 | 0.100 |
Why?
|
| Antioxidants | 1 | 2014 | 224 | 0.090 |
Why?
|
| Ergonomics | 1 | 2009 | 2 | 0.080 |
Why?
|
| Perfusion | 2 | 2021 | 43 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2016 | 5 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2025 | 27 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 191 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 843 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 84 | 0.050 |
Why?
|
| Vibration | 1 | 2022 | 78 | 0.050 |
Why?
|
| Arterioles | 1 | 2022 | 61 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 11 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2021 | 24 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 47 | 0.040 |
Why?
|
| Animals | 1 | 2015 | 10715 | 0.040 |
Why?
|
| Mitochondria | 1 | 2025 | 410 | 0.040 |
Why?
|
| Reaction Time | 1 | 2021 | 95 | 0.040 |
Why?
|
| Knee | 1 | 2021 | 25 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2021 | 58 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2021 | 64 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 1619 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 153 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2025 | 678 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 136 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 2067 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2021 | 207 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 739 | 0.040 |
Why?
|
| Diffusion | 1 | 2019 | 39 | 0.040 |
Why?
|
| Neurons | 1 | 2021 | 297 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 22 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 113 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 96 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2015 | 85 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2014 | 9 | 0.030 |
Why?
|
| Dementia | 1 | 2016 | 97 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 94 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 118 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 740 | 0.030 |
Why?
|
| Motor Activity | 1 | 2014 | 148 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 469 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 169 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 687 | 0.020 |
Why?
|